The patients were stratified into different subgroups, including patients with postoperative chemotherapy, patients without postoperative chemotherapy, patients with BRAF gene mutation, patients whose KRAS gene and BRAF gene were both wild‐type, patients with left‐sided CRC, patients with right‐sided CRC, and patients with rectum carcinoma. This evidence concerns the gene KRAS and colorectal carcinoma.